• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Evolution of the IRA: A New-Year, a Potential New Administration, Yet Tackling the Same Access and Affordability Challenges

Wednesday, June 05, 2024
Breakout Session
Value‚ Patient Access and Reimbursement
23BC
What is really going to happen with IRA impact on drug access in 2024 and 2025? How should pharma and biotech companies be preparing for future access to their treatments? As our industry enters the second year of the IRA provisions, biopharmaceutical companies are facing significant challenges to their access models: OOP caps, changes to Medicare Part D design, and the impact of this legislations to all stakeholders in the channel is starting to be felt. Hear from panelists across manufacturers, payers, and policy experts as they outline the upstream and downstream impacts of the implementation of IRA in the coming year and what your company can do to optimize access for your treatments no matter what stage of development you are in.
Moderator
Stephen Morales, MBA
Senior Principal
Blue Fin Group, An IntegriChain Company
Speakers
Gerry Gleeson
Head of US Market Access
Sanofi
Bill Sarraille
Albert Thigpen
Bill Roth
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS